Dianthus Therapeutics DNTH Other Assets And Restricted Cash
Other Assets And Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:OtherAssetsAndRestrictedCash.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's other assets and restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's other assets and restricted cash?
- Dianthus Therapeutics (DNTH) reported other assets and restricted cash of $11.54M in Q1 2026.
- How has Dianthus Therapeutics's other assets and restricted cash changed year-over-year?
- Dianthus Therapeutics's other assets and restricted cash increased by 51.1% year-over-year, from $7.64M to $11.54M.
- What is the long-term trend for Dianthus Therapeutics's other assets and restricted cash?
- Over 3 years (2022 to 2025), Dianthus Therapeutics's other assets and restricted cash has grown at a 331.4% compound annual growth rate (CAGR), from $121K to $9.72M.
- What does other assets and restricted cash mean?
- This category aggregates long-term assets that do not fit into standard classifications, including cash balances held in escrow or subject to legal or contractual restrictions. These funds are typically earmarked for specific obligations such as collateral for lease agreements, debt covenants, or long-term project commitments. Investors track this to understand the portion of the company's capital that is not available for general operational or strategic use.